Literature DB >> 1192354

Comparison of serum concentrations of methotrexate after various routes of administration.

M Freeman-Narrod, B J Gerstley, P F Engstrom, R S Bornstein.   

Abstract

Serum concentrations of methotrexate (MTX) were compared in 20 patients after administration of 15 mg/m2 MTX orally, intramuscularly, orally in divided doses, and/or intravenously. Higher and more sustained concentrations usually occurred after intramuscular administration of the drug. Approximately 50% of the patients had measurable serum concentrations 24 hours after a dose, except when the drug was given intravenously. In patients continued on MTX twice a week antimetabolic effects appeared sooner in persons with more sustained serum levels.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1192354     DOI: 10.1002/1097-0142(197511)36:5<1619::aid-cncr2820360514>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.

Authors:  F Bressolle; C Bologna; L Edno; J C Bernard; R Gomeni; J Sany; B Combe
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

2.  Role of Single-Agent Methotrexate as a Neoadjuvant Chemotherapy in Oral Cavity Cancers.

Authors:  Amol Deshpande; Vipul V Nandu; Jaideep Jadhav
Journal:  Indian J Surg Oncol       Date:  2018-12-19

Review 3.  Optimizing Methotrexate Treatment in Rheumatoid Arthritis: The Case for Subcutaneous Methotrexate Prior to Biologics.

Authors:  Poonam Sharma; David G I Scott
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

5.  Bioavailability of methotrexate: implications for clinical use.

Authors:  J F Stuart; K C Calman; J Watters; J Paxton; B Whiting; J R Lawrence; W H Steele; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 6.  Clinical pharmacokinetics of methotrexate in children.

Authors:  Y M Wang; T Fujimoto
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

7.  The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle.

Authors:  V J Harvey; M L Slevin; R C Woollard; A Johnston; M J Barnett; P F Wrigley; P Turner
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 8.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 9.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

10.  Serum profiles and safety of intermediate-dose (500-1,000 mg) methotrexate following IV and IM administration.

Authors:  B M Colls; R A Robson; B A Robinson; G W Tisch
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.